{"id":"W2135293060","doi":"10.1517/14712590903110709","title":"Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; McGill University","funders":"","keywords":"Nimotuzumab; Medicine; Monoclonal antibody; Clinical trial; Pharmacology; Epidermal growth factor receptor; Drug; Toxicity; EGFR inhibitors; Oncology; Cancer research; Cancer; Antibody; Immunology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003448822,0.001298377,0.004167253,0.0002589756,0.0004172919,0.00007935866,0.0004101278,0.001020518,0.0003300298],"category_scores_gemma":[0.00008583569,0.0007433968,0.001571394,0.0005012535,0.000290175,0.0000981961,0.0001524791,0.00088296,0.00004724184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006989323,"about_ca_system_score_gemma":0.0002479433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000702429,"about_ca_topic_score_gemma":0.000002118523,"domain_scores_codex":[0.9959717,0.0003608028,0.0007353858,0.00156149,0.0005037365,0.0008668569],"domain_scores_gemma":[0.997849,0.0004627547,0.0005352516,0.0007507229,0.0001028266,0.0002994468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007450138,0.002583176,0.0003018441,0.0001555789,0.0008492359,0.00005099306,0.0001557824,3.027832e-7,0.0006098126,0.0001142883,0.001433107,0.9930009],"study_design_scores_gemma":[0.002216731,0.004392953,0.007154064,0.003854722,0.00001803341,0.000100146,0.00004904362,0.000008826602,0.0003900389,0.00001639388,0.9809833,0.0008157663],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01133617,0.9819087,0.00007059213,0.00098341,0.001053227,0.00220584,0.0001788479,0.0002566845,0.002006565],"genre_scores_gemma":[0.01465535,0.9811503,0.0004213032,0.001365402,0.001425454,0.0002625242,0.0005722719,0.00007511872,0.00007224512],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9921851,"threshold_uncertainty_score":0.9999768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2533466771946822,"score_gpt":0.4340411261167223,"score_spread":0.1806944489220401,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}